LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.
about
Leukemia inhibitory factor (LIF)KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells.LIF is a new p53 negative regulatorBAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model.The regulation of leukemia inhibitory factor.Inhibitor of Differentiation/DNA Binding 1 (ID1) Inhibits Etoposide-induced Apoptosis in a c-Jun/c-Fos-dependent Manner.Targeting HCCR expression resensitizes gastric cancer cells to chemotherapy via down-regulating the activation of STAT3.Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 inductionInterleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression.LncSubpathway: a novel approach for identifying dysfunctional subpathways associated with risk lncRNAs by integrating lncRNA and mRNA expression profiles and pathway topologies.Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.Leukemia inhibitory factor promotes tumor growth and metastasis in human osteosarcoma via activating STAT3.Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis.Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation.Negative auto-regulators trap p53 in their web.The Id-protein family in developmental and cancer-associated pathways.Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis.Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B.TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma.TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.STAT3/p53 pathway activation disrupts IFN-β-induced dormancy in tumor-repopulating cells.Magnolin promotes autophagy and cell cycle arrest via blocking LIF/Stat3/Mcl-1 axis in human colorectal cancers.Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinomaSTAT3-Inducible Mouse ESCs: A Model to Study the Role of STAT3 in ESC Maintenance and Lineage DifferentiationLycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by Targeting STAT3
P2860
Q28082576-16604EC3-7476-499F-A4D7-19B8469587FAQ33580494-2986194F-B30E-4AA6-8AC7-7C067F0C4A7FQ35552029-9E3ED375-F5C2-48B2-A55C-76C088544B42Q35825750-ED26D5FD-5208-4803-A64B-AD3DE6659FC3Q36032139-2F94DBEB-D3DF-4643-AB0E-325478223FD0Q36049982-D5F40889-5DF3-43C0-A902-460347179541Q36206925-50734DF7-F1DD-4AE3-89FF-5F5DBF644735Q36490460-E854CE71-E366-4665-B52A-9FA3A58966D0Q36727380-7976F9C7-04ED-4F4D-A4DF-0CEB6E32C9A0Q36774158-DD83BC43-2226-40E4-A585-8160D9C19C4BQ36782261-539B3718-FAFB-441D-9329-89952215121CQ37641567-6E5B37B1-1426-466B-8DA6-F17BFE87357DQ37716567-D0935520-AEE9-476F-962F-D62BCDC8F276Q38841880-55A5F1D8-2A4F-458D-BD62-8106FBE9AF2AQ38843941-E98C3A51-245C-4A88-8C7A-73CA894BCDD1Q38889305-628AFBE5-F48E-45DF-975C-B1567C5E4F00Q38926814-D50A763E-8415-4D2F-9902-3C1B01E6972DQ38973422-2082A6D6-15CD-420A-A970-588AFFC52FA8Q39077362-B7566935-45AD-4818-995D-F2D4104ADA8AQ39103288-5C77328A-4AA8-4111-865B-3DC724335955Q39229004-E6CAA995-A08A-498B-BE27-E47235455668Q40143097-306ADCEE-42D8-44FA-B04A-790631908DA9Q41633301-D825ED27-3CDE-46E3-90EA-31726644C68FQ41926688-A010F994-2117-4BE4-9059-044193550C1FQ47279032-6E362607-0C98-4EF4-9D99-C4B7FA09E4A4Q47575245-01DCC2F6-2F64-4663-B9AE-D9D575443A10Q49406968-82E8AC7B-E934-4420-B883-C6766FC96A3AQ50066067-17BE74D7-3BEE-4B58-A04F-FD2449A1DBD7Q55267801-BFFA8459-CCB3-4D41-8666-6ECA86F6AE8CQ58739878-1DBD2A6A-0881-464E-876F-F2EAC8D108EEQ58764465-A781F2E6-9C75-44D1-8D02-244236727786Q58795453-2746034E-C969-4D32-BDFF-7A009D75DBE0
P2860
LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@ast
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@en
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@nl
type
label
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@ast
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@en
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@nl
prefLabel
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@ast
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@en
LIF negatively regulates tumou ...... D1/MDM2 in colorectal cancers.
@nl
P2093
P2860
P356
P1476
LIF negatively regulates tumou ...... ID1/MDM2 in colorectal cancers
@en
P2093
Haiyang Yu
Ken H Young
Xiaoyan Li
Xuetian Yue
Zhaohui Feng
P2860
P2888
P356
10.1038/NCOMMS6218
P407
P50
P577
2014-10-17T00:00:00Z
P5875
P6179
1036187513